ArkBio completes dosing in Australian Phase I trial of long‑acting influenza AFC drug AK0406, moving its antiviral prophylactic program forward
Executive summary: ArkBio announced that all healthy volunteer cohorts have received doses of its investigational long‑acting antiviral‑Fc conjugate (AFC) drug AK0406 in a Phase I trial conducted in Australia. The trial completion marks a key early‑stage milestone for a novel prophylactic influenza approach that could offer extended protection with fewer doses.
Who is involved: Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio), Australian clinical trial sites, and healthy volunteers.
Likely next: Top‑line safety and immunogenicity data are expected later in 2026, with a potential Phase II study contingent on favorable results.
ArkBio announced that all healthy volunteer cohorts have received doses of its investigational long‑acting antiviral‑Fc conjugate (AFC) drug AK0406 in a Phase I trial conducted in Australia. The trial’s dosing phase is now complete, setting the stage for safety and immunogenicity read‑outs later this year. As an early‑stage prophylactic influenza approach, the program could offer extended protection with fewer doses if it advances.
Timeline
- — ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406 (PR Newswire)
Analysis — what this means
Likely next events
- Top‑line safety and immunogenicity results from the Phase I trial expected Q4 2026
- If safety profile is favorable, ArkBio may initiate a Phase II study in mid‑2027
Sectors affected
- Biopharmaceuticals
- Influenza antiviral therapeutics
Regulatory implications
- Progression to Phase II will require fulfillment of IND requirements set by the FDA and EMA
- The long‑acting AFC modality may be subject to emerging guidance on Fc‑fusion protein safety
Historical parallels
- Similar long‑acting antiviral Fc‑fusion concepts were explored in early HIV broadly neutralizing antibody programs around 2020
Key entities
Sources
- ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406 — PR Newswire